Celgene International Sárl Release: New Clinical Data Evaluating ISTODAX(R) in Pivotal Open-Label Phase II Study for Patients with Peripheral T-Cell Lymphoma (PTCL)

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG) today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX®) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.